Sign Out
Type 2 diabetes mellitus: Add-on combination therapy: Forxiga is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with: Metformin; Pioglitazone; Sitagliptin (with or without metformin); Gliclazide, Glimepiride, or Glyburide (with or without metformin); Insulin (alone or with up two oral antidiabetic medications) when the existing therapy, along with diet and exercise, does not provide adequate glycemic control.
For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see Precautions, Adverse Reactions and Pharmacology: Pharmacodynamics under Actions.
Heart failure: FORXIGA is indicated in adults for the treatment of symptomatic chronic heart failure.
Chronic Kidney Disease: Forxiga is indicated in adults for the treatment of chronic kidney disease (eGFR 30-75 ml/min/1.73 m2) in reducing the risk of composite of ≥50% sustained eGFR decline, end-stage renal disease, and renal or cv death.
Lanjutkan dengan Google